Real-World Analysis of Survival and Treatment Efficacy in Stage IIIA-N2 Non-Small Cell Lung Cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Treatment for Stage IIIA-N2 non-small cell lung cancer (NSCLC) is complex, with no single approach proving superior. Personalized treatment and multidisciplinary decisions are crucial for improving survival outcomes in these patients.
Area Of Science
- Oncology
- Thoracic Surgery
- Medical Oncology
Background
- Stage IIIA-N2 non-small cell lung cancer (NSCLC) presents significant treatment challenges with limited survival rates.
- Current therapeutic strategies lack standardization, complicating patient management and outcomes.
Purpose Of The Study
- To analyze real-world data on patient outcomes for Stage IIIA-N2 NSCLC.
- To identify key predictors of overall survival (OS) and disease-free survival (DFS).
- To evaluate different treatment modalities in a real-world setting.
Main Methods
- Observational, single-centre study of 142 patients with T1/2 N2 NSCLC treated curatively (2015-2021).
- Patients categorized into: surgery for clinical N2 (Group A), unsuspected N2 during surgery (Group B), and radical chemoradiation/radiotherapy (CRT/RT) (Group C).
- Analysis of demographics, treatments, recurrence, and survival rates.
Main Results
- Median OS was 31 months (2-year OS: 60%, 5-year OS: 30%).
- Median DFS was 18 months.
- No significant difference in OS observed between treatment groups (p=0.99); ECOG status, lymphovascular invasion, and histology predicted OS.
Conclusions
- Stage IIIA-N2 NSCLC treatment is diverse, with no single superior strategy identified.
- Personalized treatment approaches and multidisciplinary decision-making are essential.
- Future research should explore novel therapies and multi-centre trials for refined strategies.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...